Back to top

Analyst Blog

Good news flowed in at RedHill Biopharma Ltd. (RDHL) when the company received a positive feedback from the UK and Swedish pharmaceutical regulatory agencies on its candidate, RHB-104. RedHill Biopharma, an Israeli biopharmaceutical company, held scientific advice meetings with the UK Medicines and Healthcare Products Regulatory Agency and the Swedish Medical Products Agency regarding the European phase III development plan of RHB-104 for Crohn's disease.

Based on the feedback from these regulatory agencies, the company plans to initiate a double-blind, placebo-controlled, phase III MAP Europe study (n = 360) to evaluate the safety and efficacy of RHB-104 in patients suffering from moderately active Crohn's disease.

RedHill Biopharma also plans to initiate a double-blind, placebo-controlled, first phase III MAP U.S. study (n = 240) on RHB-104 for the treatment of Crohn's disease in North America and Israel. The company intends to initiate the MAP U.S. study in the coming weeks and the MAP Europe study shortly after that.

Crohn's disease represents a lucrative market, which currently includes drugs like UCB’s (UCBJF) Cimzia.

Apart from Crohn’s disease, RedHill Biopharma is also evaluating the candidate for the treatment of multiple sclerosis (MS) and rheumatoid arthritis (RA). While, for the MS indication, a proof of concept phase IIa study in ongoing, for the RA indication the company plans to initiate a proof of concept phase IIa study.

RedHill Biopharma currently carries a Zacks Rank #2 (Buy). Companies that look more attractive at present include Actelion Ltd. (ALIOF) and Gilead Sciences Inc. (GILD - Analyst Report) with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 27.23 +8.99%
SUPER MICRO… SMCI 26.61 +8.66%
BANCO DO BR… BDORY 16.65 +7.21%
CANADIAN SO… CSIQ 37.75 +6.52%
WILLDAN GRO… WLDN 11.37 +5.77%